The publicly listed company Liminatus Pharma plans to raise $500 million to invest in BNB

2025-07-28 19:42:00

Collection

ChainCatcher news, according to businessinsider, the clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) announced today its plan to strategically expand into the cryptocurrency and blockchain sectors.

The company intends to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management initiatives. Through this platform, Liminatus plans to raise and deploy up to $500 million in a phased manner, aiming for strategic long-term investments in BNB.

Liminatus emphasizes that while the company remains fully committed to its core business—advancing cancer treatment and pancreatic cancer diagnostic technologies—it believes that expanding into the digital asset space is a necessary step to support long-term growth and enhance shareholder value.

Liminatus is a clinical-stage biopharmaceutical company dedicated to developing immunotherapies for cancer patients. The company is advancing a range of novel therapies targeting cancer antigens and tumor-specific immune responses.

(Source Link)

Risk warning

During the cryptocurrency market, a record of institutional crypto holdings and capital operations.

Recently, stablecoin concept stocks have continued to strengthen, with several listed companies establishing reserves of crypto assets. Stocks of crypto companies are becoming a special "crypto hotspot": traditional market investors are beginning to pay attention to companies in the crypto industry, while those in the crypto circle view the price changes of crypto stocks as one of the indicators of market fluctuations. This topic will continue to focus on the dynamics of related projects, institutional movements, market performance, and the strategic logic behind them, gaining insights into the development path of this wave of integration between crypto and equity.

Topic or theme